Tocilizumab for the treatment of TAFRO syndrome: a systematic literature review Mitsuhiro AkiyamaYuko KanekoTsutomu Takeuchi Review Article 22 September 2020 Pages: 2463 - 2475
Clozapine-induced agranulocytosis Aleksandar MijovicJames H. MacCabe Review Article Open access 20 August 2020 Pages: 2477 - 2482
Risk factors associated with increased emergency department utilization in patients with sickle cell disease: a systematic literature review Samir K. BallasCarlton Dampier Review Article 27 August 2020 Pages: 2483 - 2495
Clinical outcomes and healthcare utilization in patients with sickle cell disease: a nationwide cohort study of Medicaid beneficiaries Rishi J. DesaiMufaddal MahesriSebastian Schneeweiss Original Article 01 September 2020 Pages: 2497 - 2505
Hepatic and cardiac iron load as determined by MRI T2* in patients with congenital dyserythropoietic anemia type I Mahdi AslehAviva LevitasJoseph Kapelushnik Original Article 12 September 2020 Pages: 2507 - 2512
Treatment outcomes and chronicity predictors for primary immune thrombocytopenia: 10-year data from an academic center José Carlos Jaime-PérezPatrizia Aguilar-CalderónDavid Gómez-Almaguer Original Article 18 September 2020 Pages: 2513 - 2520
Prevalence of anaemia and associated risk factors amongst The Malaysian Cohort participants Noraidatulakma AbdullahNorliza IsmailRahman Jamal Original Article 25 September 2020 Pages: 2521 - 2527
Very long-term follow-up of aplastic anemia treated with immunosuppressive therapy or allogeneic hematopoietic cell transplantation Beatrice DrexlerFelicitas ZurbriggenJakob R. Passweg Original Article Open access 19 September 2020 Pages: 2529 - 2538
Very-low-dose decitabine treatment for patients with intermediate- or high-risk myelodysplastic syndrome: a retrospective analysis of thirteen cases Kaiji ZhangYing LianJinzhu Cao Original Article 17 September 2020 Pages: 2539 - 2546
Use of carbapenems and glycopeptides increases risk for Clostridioides difficile infections in acute myeloid leukemia patients undergoing intensive induction chemotherapy Olivier BalloEva-Maria KreiselChristian H. Brandts Original Article Open access 24 September 2020 Pages: 2547 - 2553
Real-world risk assessment and treatment initiation among patients with myelofibrosis at community oncology practices in the United States Srdan VerstovsekJingbo YuRuben Mesa Original Article Open access 07 May 2020 Pages: 2555 - 2564
Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience Huseyin BekozMurat OzbalakBurhan Ferhanoglu Original Article 07 June 2020 Pages: 2565 - 2576
Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities Norina TanakaYoichi ImaiJunji Tanaka Original Article 18 September 2020 Pages: 2577 - 2586
Correction to: Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities Norina TanakaYoichi ImaiJunji Tanaka Correction 26 September 2020 Pages: 2587 - 2587
Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study Jing LiLi BaoPeng Liu Original Article Open access 06 September 2020 Pages: 2589 - 2598
Biological properties of bone marrow plasma cells influence their recovery in aspirate specimens: impact on classification of plasma cell disorders and potential bias to evaluation of treatment response Svitlana DemyanetsAlexandra KaiderIlse Schwarzinger Original Article Open access 15 September 2020 Pages: 2599 - 2609
Detection of EP300-ZNF384 fusion in patients with acute lymphoblastic leukemia using RNA fusion gene panel sequencing Yu JingYan-Fen LiDai-Hong Liu Original Article Open access 26 September 2020 Pages: 2611 - 2617
Comparative study on allogeneic with autologous hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia in the era of TKIs: a systematic review and meta-analysis Haichen WeiPu KuangTing Liu Original Article 22 September 2020 Pages: 2619 - 2628
Association of three factors (ABCB1 gene expression, steroid response, early response at day + 8) on the response to induction in patients with acute lymphoblastic leukemia Christian Ramos-PeñafielIrma Olarte-CarrilloAdolfo Martínez-Tovar Original Article 27 September 2020 Pages: 2629 - 2637
Incidence, risk factors and outcome of extramedullary relapse after allogeneic hematopoietic stem cell transplantation in patients with adult acute lymphoblastic leukemia Jian YuXinyi GeHe Huang Original Article 05 September 2020 Pages: 2639 - 2648
A retrospective analysis on anti-CD20 antibody–treated Epstein–Barr virus–related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation Xue-Yi LuoXiao-Dong MoXiao-Jun Huang Original Article 24 March 2020 Pages: 2649 - 2657
Comparison of different cytomegalovirus diseases following haploidentical hematopoietic stem cell transplantation Xing-Ye MengHai-Xia FuXiao-Hui Zhang Original Article 30 July 2020 Pages: 2659 - 2670
Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle endemic country Ahmet MurtTugrul ElverdiTeoman Soysal Original Article 31 July 2020 Pages: 2671 - 2677
Eltrombopag treatment promotes platelet recovery and reduces platelet transfusion for patients with post-transplantation thrombocytopenia Fei GaoXiaoyu ZhouYanmin Zhao Original Article 09 June 2020 Pages: 2679 - 2687
Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A Alexander SolmsAnita ShahToshko Lissitchkov Original Article Open access 24 September 2020 Pages: 2689 - 2698
A case of allogeneic hematopoietic stem cell transplantation for primary plasma cell leukemia after treatment with daratumumab Yoshihito HorisawaTadakazu KondoAkifumi Takaori-Kondo Letter to the Editor 21 April 2020 Pages: 2699 - 2701
Residual disease by flow cytometry in patients with nucleophosmin-mutated acute myeloblastic leukemia Mengge GaoXiaosu Zhao Letter to the Editor 19 April 2020 Pages: 2703 - 2704
Myelomatous pleural effusion with plasmablastic morphology and high genetic complexity as isolated extramedullary relapse Fernando Martín-MoroAndrés RoncancioMaría J Blanchard Letter to the Editor 27 May 2020 Pages: 2705 - 2706
Expansion of paroxysmal nocturnal hemoglobinuria clones in MPLW515L mutation harboring primary myelofibrosis Keita Kirito Letter to the Editor 23 May 2020 Pages: 2707 - 2709
Atypical presentation of a central nervous system aspergillosis in a peripheral T cell lymphoma patient Mathieu LarroquetteNahéma IssaFabrice Camou Letter to the Editor 17 July 2020 Pages: 2711 - 2713
A case of “double hit” mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib Greta ScapinelloMarcello RivaFrancesco Piazza Letter to the Editor 15 July 2020 Pages: 2715 - 2717
Biallelic rare 17 bp deletion mutation (HBB:c.380_396 del TGCAGGCTGCCTATCAG) in a transfusion depended form of thalassemia Poonam TripathiSarita AgarwalKausik Mandal Letter to the Editor 15 April 2020 Pages: 2719 - 2722